コンテンツは Oncology Data Advisor® and I3 Health によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Oncology Data Advisor® and I3 Health またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!
Player FMアプリでオフラインにしPlayer FMう!
Lung Cancer Awareness Month: Treatment Updates in 2024
Manage episode 452109113 series 1163940
コンテンツは Oncology Data Advisor® and I3 Health によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Oncology Data Advisor® and I3 Health またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
As Lung Cancer Awareness Month progresses, this discussion hosted by Oncology Data Advisor sheds light on the advancements in lung cancer therapies, unmet needs, the evolving landscape of molecular testing, and actionable insights for clinicians.
…
continue reading
411 つのエピソード
Manage episode 452109113 series 1163940
コンテンツは Oncology Data Advisor® and I3 Health によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、Oncology Data Advisor® and I3 Health またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。
As Lung Cancer Awareness Month progresses, this discussion hosted by Oncology Data Advisor sheds light on the advancements in lung cancer therapies, unmet needs, the evolving landscape of molecular testing, and actionable insights for clinicians.
…
continue reading
411 つのエピソード
모든 에피소드
×1 How AI Is Revolutionizing Precision Oncology With Ian Maurer and Jasmin Hundal, MD, MS, MPH 12:49
12:49
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
12:49The role of artificial intelligence (AI) and machine learning (ML) in precision oncology has expanded rapidly, offering promising tools for clinicians and researchers to deliver more targeted and efficient care. During the 2024 San Antonio Breast Cancer Symposium (SABCS), Fellows Forum member Dr. Jasmin Hundal conducted an interview with Ian Maurer, Chief Technology Officer at GenomOncology, to explore the applications, challenges, and future directions of AI in oncology. Learn more at: https://oncfellows.com/how-ai-is-revolutionizing-precision-oncology…
1 Mendel AI: Enhancing Clinical Data Processing for Empowered Clinical Decision Making With Kristin Maloney, MS, BSN, RN, OCN®, and Waqas Haque, MD, MPH 20:43
20:43
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
20:43Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel’s innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney…
1 What’s New With HER2: Charting New Paths in NSCLC Care Module 1 Podcast: HER2 in NSCLC: Actionable Insights and Testing Recommendations 15:24
15:24
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:24Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions. In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now! Click here to claim CME/NCPD credit: https://bit.ly/49NCaQu…
1 What’s New With HER2: Charting New Paths in NSCLC Care Module 2 Podcast 18:34
18:34
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
18:34Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies. In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now! Click here to claim CME/NCPD credit: https://bit.ly/405xEJO…
1 Ontada, Microsoft, and Azure AI: Collaborating to Transform Real-Word Data Processing in Oncology 18:33
18:33
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
18:33In this episode of Exploring Artificial Intelligence in Oncology, Wanmei Ou, PhD, the Vice President of Product, Clinical Decision Support, & Analytics Data Platform at Ontada, shares more about Ontada’s collaboration with Microsoft to transform unstructured oncology data with Azure OpenAI technology. Her discussion with Dr. Waqas Haque highlights how AI is transforming clinical workflows, reducing documentation burdens, and driving improved patient outcomes. Learn more at: https://oncdata.com/ontada-microsoft-azure-ai-real-world-data-processing-in-oncology/…
1 Zanidatamab: A New Frontier in Treating HER2-Positive Biliary Tract Cancer With James Harding, MD 17:26
17:26
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
17:26The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to provide oncology clinicians with insights into its significance and implications for clinical practice. Learn more at: https://oncdata.com/zanidatamab-biliary-tract-cancer-james-harding/…
1 Lung Cancer Awareness Month: Treatment Updates in 2024 14:59
14:59
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
14:59As Lung Cancer Awareness Month progresses, this discussion hosted by Oncology Data Advisor sheds light on the advancements in lung cancer therapies, unmet needs, the evolving landscape of molecular testing, and actionable insights for clinicians.
1 Diagnosis and Management of Dedifferentiated Liposarcoma: A Multidisciplinary Task Force Podcast 28:57
28:57
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
28:57Gain valuable insights into the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) and earn free CME credit with our latest podcast. This episode features expert guidance from Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. Delve into the latest on identifying MDM2 and CDK4 amplification, challenges in diagnosing DDLPS, and updates on emerging therapies like CDK4/6 inhibitors and immunotherapies. Learn how a multidisciplinary approach enhances patient outcomes in this rare and aggressive soft tissue sarcoma. Listen now and advance your expertise! Click here to claim your CME credit: i3health.com/course-information/podcast-ddlps…
1 Clinic Conversation of the Week: How to Talk to Patients About the BENEFIT Trial in Multiple Myeloma 5:36
5:36
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
5:36The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?…
1 Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO 15:04
15:04
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:04Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO by i3 Health
1 Exclusive Sneak Peek: Unlocking What's Next in Genetic Counseling and Cancer Care! 9:30
9:30
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
9:30i3 Health is pleased to invite you to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, a free, live webinar held on November 7 at 10:00 am Eastern and November 19 at 11:30 am Eastern. This interview features an exclusive preview from the two webinar co-chairs, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center. Click below to register for this insightful webinar and enhance your understanding of genetic testing and counseling in cancer care! Register for the webinar: https://i3health.com/course-information/pathways-to-precision-integrating-genetic-counseling-and-testing-into-cancer-care…
1 Revolutionizing Cancer Diagnostics Through AI-Powered Analysis: CorePath 15:04
15:04
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
15:04In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque, MD, sits down with Aamir Ehsan, MD, the Founder and CEO of CorePath Laboratories in San Antonio, Texas. Together they discuss how CorePath utilizes AI in pathology.
1 Additional Advances in Head and Neck Squamous Cell Carcinoma With Deborah Wong, MD, PhD 9:12
9:12
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
9:12Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health’s accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With new developments in the field occurring over recent months, Dr. Wong sat down with us again to share new updates in treatment and management of HNSCC. Click here for the full activity: https://i3health.com/course-information/hnscc-harnessing-immunotherapy-in-comprehensive-care…
1 Navigating Patients Through the CKD Journey with Value-Based Care Plus CPE-Accredited Podcast 1:55:41
1:55:41
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
1:55:41Jeff Sperry, PharmD, BCPS, a Clinical Pharmacist at UCHealth Memorial Hospital, discusses additional advances in chronic kidney disease since recording the i3Health CPE-accredited activity, Slowing Progression of Chronic Kidney Disease Through Value-Based Care. Following the interview, continue listening for the complete CPE-accredited podcast. Click this link to claim your free CPE certificate: https://i3health.com/course-information/chronic-kidney-disease…
1 Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma 33:18
33:18
「あとで再生する」
「あとで再生する」
リスト
気に入り
気に入った
33:18Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma. To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm…
プレーヤーFMへようこそ!
Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。